Last reviewed · How we verify

NCT03572257

Quetiapine Treatment for Pediatric Delirium

Withdrawn Phase 2, PHASE3 Last updated 8 April 2020
What this trial tests

Phase 2, PHASE3 trial testing Quetiapine in Delirium. Withdrawn.

Timeline
15 April 2019
Primary endpoint
27 February 2020
2 March 2020

Quick facts

Lead sponsorMedical College of Wisconsin
PhasePhase 2, PHASE3
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Start date15 April 2019
Primary completion27 February 2020
Estimated completion2 March 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Medical College of Wisconsin

Who can join

Under 21, any sex, with Delirium. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, double-blind, randomized controlled trial to begin determining the efficacy of quetiapine as a treatment for pediatric delirium in patients admitted to the pediatric intensive care unit (PICU)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Quetiapine

Trials testing the same drug.

Other recruiting trials for Delirium

Currently open trials in the same condition.

Other Medical College of Wisconsin trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03572257.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing